Ligandal

The company's core technology platform is designed to be payload-agnostic, capable of encapsulating and delivering various genetic materials. This is achieved by developing proprietary nanoparticle technology that uses synthetic peptides as targeting agents. These peptides are designed computationally to bind to specific receptors on target cell surfaces, allowing for enhanced accuracy and cellular internalization while minimizing off-target effects. The firm's LigandAI® platform utilizes predictive modeling to design these peptides, aiming to accelerate the development of personalized and preventative treatments. This approach allows Ligandal to create custom delivery systems for its partners, which include biotechnology and pharmaceutical companies.

Initially focused on regenerative medicine and gene-editing applications, Ligandal pivoted during the COVID-19 pandemic to apply its technology to an immediate global health threat. It developed a peptide nanoscaffold designed to act as a dual-action antidote and vaccine for SARS-CoV-2. This therapeutic, called SARS-BLOCK, was engineered to prevent the virus from binding to human cells and simultaneously uncloak it to the immune system, thereby halting infection and stimulating a natural immune response. Beyond infectious diseases, Ligandal's primary markets include immuno-oncology and rare genetic disorders, where targeted delivery is critical for efficacy. The business model appears to be centered on both in-house therapeutic development and providing its delivery platform as a service to other life sciences companies, helping them solve the delivery challenges for their own molecules and lipid nanoparticles (LNPs).